Page 33 - GB-RI-PierreFabre-Complet-INTERACTIF

OUR CORE FIGURES OUR P Every time we care for a single pers 33 Governance guided by the public interest 86% of capital owned by the Pierre Fabre Foun- dation, a government-rec- ognized public-interest foundation 20 years of dedication by the Foundation to improving access to care and medications for people in developing countries Ahumanistic and economic project that engenders employee commitment €2.3bn revenue in 2020 9,650 employees (57% in France and 43% international) in 35 countries 86% of employees are shareholders owning an 8.25% stake in the Group A unique position combining the best of medical expertise and naturalness Nearly 800 clinical studies conducted in 2020 70% of our revenue linked to products with naturally-derived active ingredients COMPLEMENT Medical care 43% 2nd largest private pharmaceutical laboratory in France €2 A HO APPR TO H C total revenues* Listening to patients and consumers Constant dialog with patients & consumers, boosted by digital technologies LISTENING TO PATIENTS: WILL UNLOCK INNOVATION, NOW AND TOMORROW Distribution Distribution circuits that enable advice about and the sale of our products by health care professionals, giving the Group a unique relationship with pharmacists Production Over 90% of our production sites are in France with no reliance on Asia for our pharmaceutical active ingredients OUR VALUE CHAIN Research & Development An approach based on partnership and open innovation, to ensure a shorter time to market for new therapeutic and dermo-cosmetic solutions Procurement of raw materials Expertise in the extraction of plant-based active ingredients means that the active substances for products accounting for 35% of the Medical Care Business Unit’s revenues are manufactured internally CARING FOR CANCER CARING FOR CHRONIC DISEASES U o 2A . L O E A